The estimated Net Worth of Daniel Lee Flynn is at least $10.6 Milión dollars as of 16 June 2023. Mr. Flynn owns over 1,655 units of Deciphera Pharmaceuticals Inc stock worth over $1,462,673 and over the last 7 years he sold DCPH stock worth over $8,074,031. In addition, he makes $1,087,290 as Founder, Executive Vice President a Chief Scientific Officer at Deciphera Pharmaceuticals Inc.
Daniel has made over 17 trades of the Deciphera Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,655 units of DCPH stock worth $23,832 on 16 June 2023.
The largest trade he's ever made was exercising 152,927 units of Deciphera Pharmaceuticals Inc stock on 9 December 2019 worth over $289,032. On average, Daniel trades about 39,445 units every 83 days since 2017. As of 16 June 2023 he still owns at least 57,158 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr. Flynn stock trades at the bottom of the page.
Daniel Lee Flynn Ph.D. serves as Founder, Executive Vice President, Chief Scientific Officer of the Company. Dr. Flynn is our founder and has served as our Executive Vice President, Chief Scientific Officer since January 2019 and as our Chief Scientific Officer since March 2014. He previously served as our President and Chief Executive Officer from November 2003 to March 2014 and as a member of our Board of Directors from November 2003 to September 2015. Before founding Deciphera in 2003, Dr. Flynn held senior roles in small molecule chemistry with various biotechnology and pharmaceuticals companies, including as Senior Director of Chemistry with Millennium Pharmaceuticals, Director, Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dr. Flynn received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.
As the Founder, Executive Vice President a Chief Scientific Officer of Deciphera Pharmaceuticals Inc, the total compensation of Daniel Flynn at Deciphera Pharmaceuticals Inc is $1,087,290. There are 5 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Daniel Flynn is 66, he's been the Founder, Executive Vice President a Chief Scientific Officer of Deciphera Pharmaceuticals Inc since 2019. There are 2 older and 18 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar a Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: